The implant acted like scaffolding to bridge over spinal cord injuries.
Read more
Andrew Yang gives a dynamite interview on automation, UBI, and economic solutions to transitioning to the future.
Andrew Yang, award winning entrepreneur, Democratic Presidential candidate, and author of “The War on Normal People,” joins Ben to discuss the Industrial Revolution, Universal Basic Income, climate change, circumcision, and much more.
Check out more of Ben’s content on:
YouTube: https://www.youtube.com/c/benshapiro
Twitter: @benshapiro
Instagram: @officialbenshapiro
Check Andrew Yang out on:
Twitter: @ANDREWYANG
Facebook: https://www.facebook.com/andrewyang2020/
Website: https://www.yang2020.com
Read more
A revolutionary 60-minute therapy for high blood pressure could allow patients to throw their tablets away for good.
The unlikely remedy involves blasting nerves in the kidneys with sound waves to stop them sending signals to the brain that drive up blood pressure.
It could slash the risk of heart attacks and strokes, two of Britain’s biggest killers.
Read more
More drugmakers are betting gene therapies will have a big impact on patients and profits, with Pfizer Inc. last month agreeing to collaborate with Paris-based Vivet Therapeutics on a treatment for a rare liver disorder. The U.S. Food and Drug Administration forecasts as many as 20 cell- and gene-therapy approvals each year by 2025. Doubts remain about whether the treatments will sustain their dramatic results, making it difficult to determine their value.
Dozens of revolutionary gene therapies that mend faulty strands of DNA are on their way, bringing the power to eliminate lethal childhood diseases, rare blood disorders and other severe illnesses.
Beneath the excitement about these potential cures lies an important catch: no one knows how much to charge for them.
The new therapies aim to fix the root causes of disease with a single dose, and if they can replace a lifetime of conventional costly drugs, they may slash overall spending, even at multimillion-dollar prices. Yet the prospect of high costs is already stirring pushback.
Read more
